COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS
Indirect comparisons of new oral anticoagulants are performed with focus on their safety. Apixaban, an oral inhibitor of Xa factor, nowadays can be considered as a drug with very good safety profile according to randomized trials results and performed indirect comparisons.
Saved in:
| Main Authors: | V. A. Sulimov, D. A. Napalkov, A. A. Sokolova |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2015-09-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/109 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY
by: D. A. Napalkov, et al.
Published: (2015-09-01) -
PREDICTORS OF THE RISK OF HEMORRHAGIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION RECEIVING LONGTERM THERAPY WITH DIRECT ORAL ANTICOAGULANTS
by: A. А. Sokolova, et al.
Published: (2017-12-01) -
Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review
by: B. A. Tatarsky, et al.
Published: (2022-11-01) -
Safety of Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation
by: M. A. Gabitova, et al.
Published: (2020-01-01) -
Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true
by: Yu. A. Bunin, et al.
Published: (2016-09-01)